Genmab — December 2017
-
The Future of Cancer Research
My Reflections from ASH 2017 This weekend, I have the pleasure of attending the 59th Annual American Society of Hematology (ASH) Meeting & Exhibition in Atlanta, GA, alongside many members of the Janssen Hematological Malignancies team. With more than 40 data presentations for both approved and inve
(www.linkedin.com)
-
Juno's JCAR017 data var gode, men ikke gode nok. Faldt 14% https://www.fool.com/investing/2017/12/11/whats-causing-juno-therapeutics-shares-to-tumble-1.aspx
-
-
Det er meget skuffende, at der ikke blev gudet med 2018 salg
-
guidet
-
vi havde vel også i store træk hørt det meste før, der blev ihvertfald ikke hævet nogle kaniner op af hatten
-
-
God morgen.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind